5 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 5 |
Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease SAGE-718 - Huntington's Disease | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 153 | 2022-12-14 | 2025-12-17 |
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Valbenazine - Chorea, Huntington | Phase 3 | Terminated | Neurocrine Biosciences | 154 | 2020-09-18 | 2026-11-03 |
| An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease Dimebon (latrepirdine) - Huntington Disease | Phase 3 | Terminated | Medivation, Inc. | 362 | 2010-02-01 | 2016-10-12 |
| Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Creatine Monohydrate, Placebo - Huntington's Disease | Phase 3 | Terminated | Massachusetts General Hospital | 553 | 2009-09-01 | 2016-03-11 |
| Coenzyme Q10 in Huntington's Disease (HD) coenzyme Q10, placebo - Huntington's Disease | Phase 3 | Terminated | Massachusetts General Hospital | 609 | 2008-03-01 | 2016-03-30 |
Huntington Disease (5) · Mitochondrial Diseases (1)
Basal Ganglia Diseases (5) · Brain Diseases (5) · Central Nervous System Diseases (5) · Cognition Disorders (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Dementia (5) · Dyskinesias (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Mental Disorders (5) · Movement Disorders (5) · Nervous System Diseases (5) · Neurocognitive Disorders (5) · Neurodegenerative Diseases (5)
Creatine (1) · Glucose (1) · coenzyme Q10 (1) · latrepirdine (1) · valbenazine (1)
Massachusetts General Hospital (2) · Medivation, Inc. (1) · Neurocrine Biosciences (1) · Supernus Pharmaceuticals, Inc. (1)
Canada (4) · United States (4) · Australia (3) · New Zealand (1) · United Kingdom (1)
Diana Rosas, MD, MS (1) · Giovanni Schifitto, MD (1) · Karl Kieburtz, MD MPH (1) · Merit Cudkowicz, MD MSc (1) · Michael McDermott, PhD (1) · Steven M Hersch, MD, PhD (1)
PMID 35747889, PMID 27913695, PMID 28701493, PMID 30103342, PMID 30850442
R01NS052619 (1), U01AT000613 (1), U01NS052592 (1)